UJUlrich Stab Jensen

Ulrich Stab Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulrich Stab Jensen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 7 November 2011
      • Vol. 173  (45) , 2853-6

    [Notable increase in the consumption of antibiotics in general practice].

    by Ulrich Stab Jensen, Lars Bjerrum

    The antimicrobial consumption in primary health care has increased notably during the latest decade. The increase has predominantly been among broad-spectrum antimicrobial agents. Denmark is no longer among the European countries with the lowest consumption. The reasons for these changes are not fully explained, but increased dosage for each treated patient and more patients treated have played an important role. To some extent, the consumption meets with relevant quality indicators for antibiotic prescribing, but the use of resistance inducing antibiotics needs to be limited according to guidelines.


    • 7 November 2011
      • Vol. 173  (45) , 2859-62

    [Increasing antimicrobial consumption in hospitals].

    by Ulrich Stab Jensen

    The antimicrobial consumption in hospital care has increased steadily during the latest decade. Now, broad-spectrum antimicrobial agents dominate the consumption at the expense of beta-lactamase sensitive penicillins. The reasons for these changes are not fully understood, but increased activity at the hospitals, higher resistance rates and the emergence of resistant nosocomial bacterial infections have played an important role. Denmark is no longer among the European countries with the lowest consumption. This indicates the need to implement restriction on antimicrobial usage in hospital care.

  • Risk factors for recurrence and death after bacteraemia: a population-based study

    by U. S. Jensen, J. D. Knudsen, S. Wehberg, D. B. Gregson, K. B. Laupland


  • Open Access

    Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance

    by Ulrich S. Jensen, Arno Muller, Christian T. Brandt, Niels Frimodt-Møller, Anette M. Hammerum, Dominique L. Monnet, on behalf of the DANRES study group

    The introduction of generic versions of drugs has often resulted in an increase in the consumption of the agents involved. In December 2001, generic ciprofloxacin was marketed in Denmark. Our objective was to evaluate, in a community setting, the effect of price on consumption of ciprofloxacin and on ciprofloxacin resistance in Escherichia coli urine isolates. We conducted a retrospective ecological study collecting monthly national data on the number of marketed versions and primary healthcare (PHC) sales of ciprofloxacin during January 1995–December 2005. Data were compared with a median price per defined daily dose (DDD) of ciprofloxacin during September 1999–December 2005. Yearly PHC consumption data from seven Danish counties were compared with the antimicrobial resistance profiles of PHC E. coli urine isolates. During 2002, the number of marketed versions increased from 3 to 10, and the median price per DDD decreased by 53%. From 2002 to 2005, the total consumption of oral ciprofloxacin in PHC increased significantly from 0.13 DDD/1000 inhabitant-days to 0.33 DDD/1000 inhabitant-days. During the same period, the frequency of ciprofloxacin resistance increased by 200%. A statistically significant correlation was found between the consumption of ciprofloxacin and the ciprofloxacin resistance rate in E. coli urine isolates, independent of the introduction of generic ciprofloxacin. After the introduction of generic ciprofloxacin, a significant increase in the total consumption of oral ciprofloxacin in PHC was observed in Denmark. The increase in consumption was significantly correlated with ciprofloxacin resistance in E. coli obtained from urine isolates.


  • Recurrent bacteraemia: A 10-year regional population-based study of clinical and microbiological risk factors

    by Ulrich Stab Jensen, Jenny Dahl Knudsen, Christian Østergaard, Kim Oren Gradel, Niels Frimodt-Møller, Henrik Carl Schønheyder


  • Open Access

    Consequences of increased antibacterial consumption and change in pattern of antibacterial use in Danish hospitals

    by Ulrich S. Jensen, Line Skjøt-Rasmussen, Stefan S. Olsen, Niels Frimodt-Møller, Anette M. Hammerum, on behalf of the DANRES Study Group

    Antibacterial consumption is increasing in many countries around the world, and it is increasingly recognized as the main reason for the emergence of resistance. This study was implemented to analyse antibacterial consumption in public hospitals in Denmark during 2001–07 as a follow-up on a prior analysis and furthermore, to investigate the consequences of the occurrence of resistance. National data on the consumption of antibacterials for systemic use in Danish public hospitals were obtained from 2001 through 2007. Consumption data were compared with antimicrobial resistance in all isolates recorded from either blood samples (Escherichia coli and Klebsiella pneumoniae) or urine samples (E. coli) submitted for susceptibility testing to the participating Departments of Clinical Microbiology during 2001–07. The consumption of combinations of penicillins including β-lactamase inhibitors, cephalosporins, carbapenems and fluoroquinolones continued to increase from 19.2% of the total consumption in hospitals in Denmark in 2001 to 38.2% in 2007. Quinolone resistance in E. coli isolates from blood and urine samples increased significantly from 2001 through 2007. Furthermore, multiresistant K. pneumoniae emerged. The consumption of ‘broad-spectrum’ antibacterial agents has continued to increase in Danish hospitals. At the same time, an increasing resistance in clinical isolates towards the same antibacterial agents has been observed. However, more detailed information on the specific consumption of the antibacterial agents might help to restrict or reverse the increasing use of ‘broad-spectrum’ antibacterial agents and perhaps also the increasing antimicrobial resistance.